Gastric MALT-type lymphoma arising in the absence of Helicobacter pylori infection represents a specific clinical situation. Because the pathogen is not present to target, the management approach for this subgroup requires dedicated consideration distinct from H. pylori-positive disease.
Gastric MALT-type lymphoma confirmed without detectable Helicobacter pylori infection. Almost 10% of MALT lymphomas are unrelated to H. pylori infection, and the pathogenesis remains unclear.
The protocol for this scenario involves an antibiotic-based strategy. The complete regimen, supporting evidence, and full clinical algorithm are available in the structured protocol below.
The primary objective is remission of the gastric MALT lymphoma, with most responses occurring between 3 and 9 months after treatment initiation.
Almost 10% of MALT lymphomas are unrelated to H pylori infection, and the pathogenesis remains unclear.
Although no clear therapeutic guidelines have been established for those patients in whom antibiotic therapy results are unsuccessful or for those without the presence of H pylori at diagnosis, several studies have reported that a percentage of patient responded to antibiotic therapy.
Raderer et al reported that 5 of 6 patients with H pylori-negative gastric MALT lymphoma responded to antibiotic therapy, indicating an excellent response rate of 83%.
The authors also observed that most of the patients responded to antibiotic therapy between 3 and 9 months.
View source ↗